Real-world multicentre experience of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer

• Main Authors: Liam, Chong Kin, Chai, Chee Shee, Ho, Gwo Fuang, Alip, Adlinda, Abdul Wahid, Mohd Ibrahim, Abdullah, Matin Melor, Foo, Yoke Ching, How, Soon Hin, Zaatar, Adel, Lam, Kai Seng, Leong, Kin Wah, Seng Hoi, John Low, Md Yusof, Mastura
• Format: Conference or Workshop Item
• Language: English; English
• Published: 2019
• Subjects: R Medicine (General); RC731 Specialties of Internal Medicine-Diseases of The Respiratory System
• Online Access: http://irep.iium.edu.my/86231/1/WCLC2019%20poster_Real%20World%20Multicenter%20Experience%20of%20First-line%20Afatinib_25Aug2019.pdf; http://irep.iium.edu.my/86231/7/WCLC2019-Abstract-Book_web-friendly.pdf; http://irep.iium.edu.my/86231/

Background : Afatinib is an irreversible, second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that has been shown to be more potent than platinum doublet chemotherapy as well as the firstgeneration EGFR-TKI in patients with EGFR-mutant advanced non-small cell lu...